Bill Gates Throws His Weight Behind Alzheimer’s Research
The philanthropist today announced a $50 million investment in the U.K.’s Dementia Discovery Fund, which supports startups developing innovative treatments.
ALL NEWS
6538 RESULTS
Sort By:
- Most Recent
- Most Commented
Rare Genetic Variants Find Common Ground in ALS; Steer Treatment Response
In people with ALS, researchers identified 39 new genetic variations in RNA-binding proteins that may influence the disease. Such information could inform future pharmacogenomics treatment.
A New Link Between Alzheimer’s and Nasu-Hakola Disease?
A case study describes amyloidosis in a 39-year-old homozygous for a TREM2 mutation, but experts question the interpretation.
Stabilizing C9ORF72 RNA Lowers Toxicity
Small molecules that stabilize G-quadruplexes cut C9ORF72 RNA and protein deposits in half.
Clinical Trials on Alzheimer's Disease 2017
10th CTAD: Finally, Alzheimer’s Field Is Serious About Prevention Trials At CTAD, Tau PET Emerges as Favored Outcome Biomarker for Trials Automated CSF Tests: Check. Blood Tests: In the Works Cognitive Testing Is Getting Faster and Better Don’t Be an Enro
10th CTAD: Finally, Alzheimer’s Field Is Serious About Prevention Trials
Alzheimer’s science has undergone a paradigm shift toward the disease’s silent phase. For trials, this means change at every level: new participants, new screening tools, new outcome measurements. What’s the progress?
ApoE4 Promotes Amyloidosis, But Only in Plaque-Free Mice
Two complementary studies find that ApoE4 has little influence on plaques once they are present.
At CTAD, Tau PET Emerges as Favored Outcome Biomarker for Trials
Tau’s apparent lockstep with cognitive decline dominated the PET conversation. Piramal flaunted data, and Merck/Cerveau are close behind. A first stab at imaging synapses in the hippocampus drew notice, too.
Cognitive Testing Is Getting Faster and Better
Who doesn’t dread hours of testing at a clinic? Innovation needed! Learn about frequent “burst” testing via mobile app, and a digital pen that captures more information than the old paper-and-pencil test.
Don’t Be an Enrollment Loser: Throw Your Own Swab-a-Palooza!
Recruitment, recruitment, recruitment: Registries get creative in how they promote research engagement and fill prevention trials.
Verubecestat Negative Trial Data: What Does it Mean for BACE Inhibition?
Presented at CTAD, BACE inhibitor’s efficacy and safety results in mild to moderate AD were encouraging to some clinicians, vaguely disquieting to others.
High-Dose Gantenerumab Lowers Plaque Load
Gradually raising the dose of this therapeutic antibody appears to ease the risk of brain inflammation.
Pimavanserin Trial Raises Hope for Treating Dementia-Related Psychosis
In a Phase 2 trial in nursing home residents with Alzheimer’s, this new drug mitigated symptoms safely, without detriment to cognition.
Blood, the Secret Sauce? Focus on Plasma Promises AD Treatment
Phase 1 trial tests the rejuvenating effects of young blood, while albumin replacement may offer its own benefits.
Elusive or Not, Aβ Oligomers Are in BioPharma Crosshairs
Ephemeral as they may be, these maligned peptides have become the targets of small-molecule and immunotherapies. Initial results of these efforts to catch and remove Aβ oligomers are trickling in.
Current Filters
No filters selected